About Fezolinetant API
Therapeutic CategoryGyneacology
CAS Number
1629229-37-3
API Technology
Synthetic
Dose Form
Oral Solid/Tablets
Dr Reddy's Development Status
Under Development
Mechanism of Action
Fezolinetant is an oral, nonhormone therapy in clinical development for treating moderate/severe menopausal VMS. Fezolinetant is a neurokinin 3 receptor antagonist that blocks NKB signalling, thereby normalizing the activity of KNDy neurons in the thermoregulatory centre of the brain and reducing VMS.
Indication
Veozah (fezolinetant) is a selective neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
Related APIs
Fezolinetant
Gyneacology
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!